This AACE consensus statement was developed by a multidisciplinary task force, which included medical professionals in endocrinology, endocrine surgery, surgical oncology, genetics, and clinical research as well as a patient representative, who conducted a targeted review of the literature to provide practical patient-centered clinical guidance for practitioners who care for individuals with MEN1.
Read Consensus Statement
Commentary:
Review commentary on the consensus statement from the patient representative on the task force, Dr. Jason Keller.
Read Commentary
AACE Podcasts Episode 60: 2025 AACE MEN1 Consensus Statement Overview
Join Dr. David Lieb as he moderates a discussion with Dr. Jaydira Del Rivero, Chair of the MEN1 Consensus Statement Task Force, and Dr. Michelle Lundholm, Methodology Fellow, about the recently released 2025 AACE Consensus Statement on the Management of Multiple Endocrine Neoplasia, Type 1 (MEN1).
This episode covers:
- AACE’s updated consensus statement methodology, including the new methodology fellow and patient representative roles
- The role of surgical and non-surgical management strategies for patients with different types of MEN1-related tumors
- The importance of patient values and preferences and risks/benefits of different screening modalities when determining appropriate screening frequencies for patients
- Current gaps in the literature and future considerations for MEN1 research